Clinical Trial Update: Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of CGC-11047 in metastatic hormone-refractory prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CGC-11047 (PG-11047)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED